Prominent celecoxib researcher admits fabricating data in 21 articlesBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b966 (Published 09 March 2009) Cite this as: BMJ 2009;338:b966
- Jeanne Lenzer
- 1New York
A well known researcher who promoted the use of the non-steroidal anti-inflammatory drug celecoxib has admitted fabricating data in 21 of his 72 articles indexed by PubMed. The case is “among the biggest which has come to light,” said Harvey Marcovitch, chairman of the Committee on Publication Ethics, an international forum for publishers and editors of peer reviewed journals.
Scott S Reuben, chief of the acute pain service at Baystate Medical Center in Springfield, Massachusetts, has admitted the fraud, says a notice issued by the centre in late January.
Jane Albert, a spokeswoman for the centre, a teaching hospital that serves as a campus of Tufts University School of Medicine, said that after evaluating the 51 other articles by Dr …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial